{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lowenthal ED"],"funding":["National Institute of Allergy and Infectious Diseases","Eunice Kennedy Shriver National Institute of Child Health and Human Development","NICHD NIH HHS","NIAID NIH HHS","National Institute of Mental Health","National Institutes of Health","International Maternal Pediatric Adolescent AIDS Clinical Trials Network"],"pagination":["e222-e232"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11061207"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(4)"],"pubmed_abstract":["<h4>Background</h4>Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12-17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.<h4>Methods</h4>In this a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study, with continuation of pre-study oral combination antiretroviral treatment (ART), 55 adolescents living with HIV-1 were enrolled to receive sequential doses of either long-acting cabotegravir or rilpivirine and 52 received at least two injections. Participants had a body weight greater than 35 kg and "],"journal":["The lancet. HIV"],"pubmed_title":["Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study."],"pmcid":["PMC11061207"],"funding_grant_id":["UM1 AI068632","UM1AI068616","UM1 AI106716","HHSN275201800001I","UM1AI106716","U01 AI069463","HHSN275201800001C","UM1 AI068616","UM1AI068632","UM1 AI069463","U01 AI068632","UM1 AI069399"],"pubmed_authors":["Zabih S","Naidoo M","Harrington C","Whitson K","Camacho-Gonzalez A","Huang J","Buisson S","Paul ME","Ward S","Van Solingen-Ristea RM","Crauwels H","IMPAACT 2017 Team","Gaur AH","Adeyeye A","Best BM","Hanley S","Patel F","Lowenthal ED","Agwu AL","Capparelli EV","Townley E","Chounta V","Bearden A","Bolton-Moore C","McCoig CC","Mathiba SR","Smith-Anderson C","Calabrese K","Ounchanum P","Vandermeulen K","Kneebone J","Heckman B","D'Angelo J","Milligan R","Ohrenschall R","Yin DE","Chapman J","Baltrusaitis K","IMPAACT 2017 Collaborators"],"additional_accession":[]},"is_claimable":false,"name":"Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.","description":"<h4>Background</h4>Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12-17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.<h4>Methods</h4>In this a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study, with continuation of pre-study oral combination antiretroviral treatment (ART), 55 adolescents living with HIV-1 were enrolled to receive sequential doses of either long-acting cabotegravir or rilpivirine and 52 received at least two injections. Participants had a body weight greater than 35 kg and ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T14:42:55.751Z","creation":"2026-04-08T13:24:04.498Z"},"accession":"S-EPMC11061207","cross_references":{"pubmed":["38538161"],"doi":["10.1016/s2352-3018(23)00301-6","10.1016/S2352-3018(23)00301-6"]}}